Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The linDNA-LNP vaccine, designed and manufactured, will be used in upcoming in vivo animal studies to assess the performance of linDNA-LNP vaccines and will inform the final design of the company’s lead veterinary asset, a linDNA-LNP canine lymphoma vaccine candidate.
Lead Product(s): LinearDNA SARS-CoV-2 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: EvviVax
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2022